The history and pharmacology of dopamine agonists
- PMID: 6713309
- DOI: 10.1017/s0317167100046266
The history and pharmacology of dopamine agonists
Abstract
The recognition of the dopaminergic properties of some ergot derivatives has initiated new therapeutical approaches in endocrinology as well as in neurology. The pharmacological characterization of the different ergot derivatives during the last decade has largely improved our understanding of central dopaminergic systems. Their development has yielded valuable information on the pharmacology of dopamine receptors involved in the regulatory mechanisms of prolactin secretion and in striatal functions. The clinical application of such new neurobiological concepts has underlined the therapeutical interest of such compounds either in the control of prolactin-dependent endocrine disorders or in the treatment of parkinsonism. Owing to their pharmacological profiles, dopaminergic agonists represent a valuable clinical option especially in the management of Parkinson's disease in view of the problems arising from chronic L-Dopa treatment.
Similar articles
-
Dopamine agonists in Parkinson's disease.Can J Neurol Sci. 1984 Feb;11(1 Suppl):221-4. doi: 10.1017/s0317167100046448. Can J Neurol Sci. 1984. PMID: 6231979
-
DA agonists -- ergot derivatives: cabergoline: management of Parkinson's disease.Mov Disord. 2002;17 Suppl 4:S68-71. doi: 10.1002/mds.5563. Mov Disord. 2002. PMID: 12211142 Review. No abstract available.
-
DA agonists -- ergot derivatives: dihydroergocryptine (DHEC): management of Parkinson's disease.Mov Disord. 2002;17 Suppl 4:S72-3. doi: 10.1002/mds.5564. Mov Disord. 2002. PMID: 12211143 Review. No abstract available.
-
DA agonists -- ergot derivatives: pergolide: management of Parkinson's disease.Mov Disord. 2002;17 Suppl 4:S79-82. doi: 10.1002/mds.5566. Mov Disord. 2002. PMID: 12211145 Review. No abstract available.
-
DA agonists -- ergot derivatives: lisuride: management of Parkinson's disease.Mov Disord. 2002;17 Suppl 4:S74-8. doi: 10.1002/mds.5565. Mov Disord. 2002. PMID: 12211144 Review. No abstract available.
Cited by
-
Adopting the Rumsfeld approach to understanding the action of levodopa and apomorphine in Parkinson's disease.J Neural Transm (Vienna). 2023 Nov;130(11):1337-1347. doi: 10.1007/s00702-023-02655-0. Epub 2023 May 20. J Neural Transm (Vienna). 2023. PMID: 37210460 Free PMC article. Review.